Boothbay Fund Management LLC Sells 60,412 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Boothbay Fund Management LLC decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,324,221 shares of the biotechnology company's stock after selling 60,412 shares during the period. Boothbay Fund Management LLC owned about 0.63% of BioCryst Pharmaceuticals worth $9,932,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Allianz Asset Management GmbH raised its stake in BioCryst Pharmaceuticals by 9.6% in the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 1,200 shares during the period. Royal Bank of Canada boosted its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after buying an additional 1,458 shares during the period. SG Americas Securities LLC grew its stake in BioCryst Pharmaceuticals by 5.2% in the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after buying an additional 2,146 shares during the last quarter. Wellington Management Group LLP raised its holdings in BioCryst Pharmaceuticals by 2.6% in the 1st quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company's stock valued at $685,000 after acquiring an additional 2,291 shares during the period. Finally, Mariner LLC lifted its position in BioCryst Pharmaceuticals by 32.1% during the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 3,224 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $8.29 on Thursday. The firm has a market capitalization of $1.74 billion, a PE ratio of -46.05, a price-to-earnings-growth ratio of 1.89 and a beta of 1.13. The stock's 50-day simple moving average is $8.57 and its 200 day simple moving average is $8.77. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

BCRX has been the subject of several research reports. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 1st. Finally, Wedbush lifted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, June 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $16.70.

Read Our Latest Analysis on BioCryst Pharmaceuticals

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

• Five stocks we like better than BioCryst Pharmaceuticals
• Technology Stocks Explained: Here's What to Know About Tech
• Return of the ETFs: 3 Names That Could Keep Outperforming
• Stock Splits, Do They Really Impact Investors?
• Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now
• 3 Warren Buffett Stocks to Buy Now
• Alphabet Stock Surges After Dodging Harsh Antitrust Remedies

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?

Before you consider BioCryst Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.

While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here